Human Papilloma Virus Partnering 2009-2014

  • November 2014
  • -
  • Currentpartnering
  • -
  • 100 pages

The Human Papilloma Virus Partnering 2009-2014 report provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

-Trends in human papilloma virus partnering deals
-Top human papilloma virus deals by value
-Deals listed by company A-Z, industry sector, stage of development, technology type

The Human Papilloma Virus Partnering 2009-2014 provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of human papilloma virus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors human papilloma virus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 70 links to online copies of actual human papilloma virus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of human papilloma virus partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in human papilloma virus partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading human papilloma virus deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of human papilloma virus partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of human papilloma virus technologies and products.

Report scope

Human Papilloma Virus Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to human papilloma virus trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

-Trends in human papilloma virus dealmaking in the biopharma industry since 2009
-Access to summary headline, upfront, milestone and royalty data
-The leading human papilloma virus deals by value since 2009

In Human Papilloma Virus Partnering 2009-2014, the available deals are listed by:

-Headline value
-Upfront payment value
-Royalty rate value
-Company A-Z
-Industry sector
-Stage of development at signing
-Deal component type
-Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Human Papilloma Virus Partnering 2009-2014
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in human papilloma virus partnering

2.1. Introduction
2.2. Human papilloma virus partnering over the years
2.3. Big pharma human papilloma virus dealmaking activity
2.4. Big biotech human papilloma virus dealmaking activity
2.5. Most active human papilloma virus dealmakers
2.6. Human papilloma virus partnering by deal type
2.7. Human papilloma virus partnering industry sector
2.8. Human papilloma virus partnering by stage of development
2.9. Human papilloma virus partnering by technology type
2.10. Disclosed financial deal terms for human papilloma virus
2.10.1 Human papilloma virus headline values
2.10.2 Human papilloma virus upfront payments
2.10.3 Human papilloma virus milestone payments
2.10.4 Human papilloma virus royalty rates

Chapter 3 - Leading human papilloma virus deals

3.1. Introduction
3.2. Top human papilloma virus deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Human papilloma virus partnering since 2009
Figure 2: Big pharma - top 50 - human papilloma virus deals 2009 to 2014
Figure 3: Big pharma human papilloma virus deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - human papilloma virus deals 2009 to 2014
Figure 5: Big biotech human papilloma virus deal frequency - 2009 to 2014
Figure 6: Human papilloma virus dealmaking activity- 2009 to 2014
Figure 7: Human papilloma virus partnering by deal type since 2009
Figure 8: Human papilloma virus partnering by industry sector since 2009
Figure 9: Human papilloma virus partnering by stage of development since 2009
Figure 10: Human papilloma virus partnering by technology type since 2009
Figure 11: Human papilloma virus deals with a headline value
Figure 12: Human papilloma virus deals with upfront payment values
Figure 13: Human papilloma virus deals with milestone payments
Figure 14: Human papilloma virus deals with royalty rates, %
Figure 15: Top human papilloma virus deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ...

Asia-Pacific Markets for Dental Bone Graft Substitutes and Barrier Membranes

Asia-Pacific Markets for Dental Bone Graft Substitutes and Barrier Membranes

  • $ 7 995
  • Industry report
  • April 2015
  • by iData Research, Inc.

The loss of bone can cause discomfort and prevent patients from receiving dental implants. Bone grafting procedures using bone graft substitutes (BGS) are performed to repair bone loss. Bone grafting can ...

Plerixafor  - Comprehensive patent search

Plerixafor - Comprehensive patent search

  • $ 8 160
  • Industry report
  • March 2015
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Biosimilars: Global Markets

January 2015 $ 6 650

Download Unlimited Documents from Trusted Public Sources

Quantum Dot Market in the US

  • April 2015
    3 pages
  • Nanostructure  

    Quantum Dot  

  • United States  

View report >

Biological Therapy Industry in Canada

  • April 2015
    9 pages
  • Biological Ther...  

  • Canada  

View report >

Blood Supply

  • April 2015
    2 pages
  • Blood Supply  

    Oncology  

    Chemotherapy  

View report >

Rna Supply

13 days ago

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.